Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: Broad-spectrum antibacterial agents with reduced hERG activity

Journal of Medicinal Chemistry

Volumn 54, Issue 22, 2011, Pages 7834-7847

  Reck, Folkert ^a   Alm, Richard ^a   Brassil, Patrick ^a   Newman, Joseph ^a   Dejonge, Boudewijn ^a   Eyermann, Charles J ^a   Breault, Gloria ^a   Breen, John ^a   Comita Prevoir, Janelle ^a   Cronin, Mark ^a   Davis, Hajnalka ^a   Ehmann, David ^a   Galullo, Vincent ^a   Geng, Bolin ^a   Grebe, Tyler ^a   Morningstar, Marshall ^a   Walker, Phil ^a   Hayter, Barry ^a   Fisher, Stewart ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [ 2 [ 4 [( 2,3 DIHYDRO[ 1,4 ]DIOXINO[ 2,3 C]PYRIDIN 7 YL METHYL)AMINO]PIPERIDIN 1 YL]ETHYL] 7 METHOXYQUINOXALIN 2 (1H) ONE; 3 OXO 4 [ 2 ( 4 [[( 3 OXO 3,4 DIHYDRO 2H PYRIDO[ 3,2 B][ 1,4 ]OXAZIN 6 YL)METHYL]AMINO]PIPERIDIN 1 YL)ETHYL] 3,4 DIHYDRO 2H 1,4 BENZOXAZINE 6 CARBONITRILE; AMIDE; AMINOPIPERIDINE DERIVATIVE; ANTIBIOTIC AGENT; BENZOXAZINE DERIVATIVE; GYRASE INHIBITOR; LEVOFLOXACIN; POTASSIUM CHANNEL HERG; QUINOLONE; QUINOLONE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS LINKING; CROSS RESISTANCE; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; FRACTIONATION; GROWTH INHIBITION; IC 50; MOUSE; NONHUMAN; PHYSICOCHEMICAL MODEL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA TOPOISOMERASES, TYPE II; DOGS; DRUG RESISTANCE, BACTERIAL; ETHER-A-GO-GO POTASSIUM CHANNELS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; PIPERIDINES; PROTEIN CONFORMATION; RATS; STAPHYLOCOCCAL INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE INHIBITORS;

EID: 81555223850     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2008826     Document Type: Article

References (39)

1. Zhanel, G. G.; DeCorby, M.; Adam, H.; Mulvey, M. R.; McCracken, M.; Lagace-Wiens, P.; Nichol, K. A.; Wierzbowski, A.; Baudry, P. J.; Tailor, F.; Karlowsky, J. A.; Walkty, A.; Schweizer, F.; Johnson, J.; Hoban, D. J. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian ward surveillance study (CANWARD 2008) Antimicrob. Agents Chemother. 2010, 54, 4684-4693
2. Bax, B. D.; Chan, P. F.; Eggleston, D. S.; Fosberry, A.; Gentry, D. R.; Gorrec, F.; Giordano, I.; Hann, M. M.; Hennessy, A.; Hibbs, M.; Huang, J.; Jones, E.; Jones, J.; Brown, K. K.; Lewis, C. J.; May, E. W.; Saunders, M. R.; Singh, O.; Spitzfaden, C. E.; Shen, C.; Shillings, A.; Theobald, A. J.; Wohlkonig, A.; Pearson, N. D.; Gwynn, M. N. Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 2010, 466, 935-940
3. Wiener, J. J. M.; Gomez, L.; Venkatesan, H.; Santillan, A., Jr. ; Allison, B. D.; Schwarz, K. L.; Shinde, S.; Tang, L.; Hack, M. D.; Morrow, B. J.; Motley, S. T.; Goldschmidt, R. M.; Shaw, K. J.; Jones, T. K.; Grice, C. A. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains Bioorg. Med. Chem. Lett. 2007, 17, 2718-2722 (Pubitemid 46636268)
4. Black, M. T.; Stachyra, T.; Platel, D.; Girard, A.; Claudon, M.; Bruneau, J.; Miossec, C. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases Antimicrob. Agents Chemother. 2008, 52, 3339-3349
5. Breault, G.; Eyermann, C. J.; Geng, B.; Morningstar, M.; Reck, F. WO2006134378, 2006.
6. Axten, J. M.; Brooks, G.; Brown, P.; Davies, D.; Gallagher, T. F.; Markwell, R. E.; Miller, W. H.; Pearson, N. D.; Seefeld, M. WO004058144, 2004.
7. Kiyoto, T.; Tanaka, T.; Tsutsui, Y.; Ando, J.; Motono, M.; Kawaguchi, Y.; Noguchi, T.; Ushiki, Y.; Ushiyama, F.; Urabe, H. WO2006137485, 2006.
8. Gauvin, J.; Hubschwerlen, C.; Surivet, J.; Zumbrunn Acklin, C. WO2007105154, 2007.
9. Inagaki, H.; Fujisawa, T.; Itoh, M.; Hayakawa, M.; Tsuda, T.; Nagamochi, M.; Takahashi, H.; Takemura, M. WO2009125809, 2009.
10. Gaucher, B.; Danel, F. H.; Roussel, P. WO2010084152, 2010.
11. Black, M. T.; Coleman, K. New inhibitors of bacterial topoisomerase GyrA/ParC subunits Curr. Opin. Invest. Drugs 2009, 10, 804-810
12. McMartin, C.; Bohacek, R. S. Flexible matching of test ligands to a 3D pharmacophore using a molecular superposition force field: comparison of predicted and experimental conformations of inhibitors of three enzymes J. Comput.-Aided Mol. Des. 1995, 9, 237-250
13. Barrett, J. F.; Sutcliffe, J. A.; Gootz, T. D. In vitro assays used to measure the activity of topoisomerases Antimicrob. Agents Chemother. 1990, 34, 1-7 (Pubitemid 20019953)
14. Barfoot, C. W.; Brown, P.; Dabbs, S.; Davies, D. T.; Hennessy, A. J.; Miles, T. J.; Pearson, N. D. The design of efficient and selective routes to pyridyl analogues of 2,3-dihydro-1,4-benzodioxin-6-carbaldehyde Tetrahedron Lett. 2010, 51, 5038-5040
15. Brooks, G.; Dabbs, S.; Davies, D. T.; Hennessy, A. J.; Jones, G. E.; Markwell, R. E.; Miles, T. J.; Owston, N. A.; Pearson, N. D.; Peng, T. W. The design of efficient and selective routes to pyridyl analogues of 3-oxo-3,4-dihydro-2 H -1,4-(benzothiazine or benzoxazine)-6-carbaldehydes Tetrahedron Lett. 2010, 51, 5035-5037
16. Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
17. O'Shea, R.; Moser, H. E. Physicochemical properties of antibacterial compounds: implications for drug discovery J. Med. Chem. 2008, 51, 2871-2878 (Pubitemid 351706014)
18. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited Microbiol. Mol. Biol. Rev. 2003, 67, 593-656 (Pubitemid 37549772)
19. Bridgland-Taylor, M. H.; Hargreaves, A. C.; Easter, A.; Orme, A.; Henthorn, D. C.; Ding, M.; Davis, A. M.; Small, B. G.; Heapy, C. G.; Abi-Gerges, N.; Persson, F.; Jacobson, I.; Sullivan, M.; Albertson, N.; Hammond, T. G.; Sullivan, E.; Valentin, J. P.; Pollard, C. E. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT J. Pharmacol. Toxicol. Methods 2006, 54, 189-199 (Pubitemid 44308866)
20. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard, 2nd ed.; National Committee for Clinical Laboratory Standards: Villanova, PA, 1993.
21. Lanzetta, P. A.; Alvarez, L. J.; Reinach, P. S.; Candia, O. A. An improved assay for nanomole amounts of inorganic phosphate Anal. Biochem. 1979, 100, 95-97 (Pubitemid 10157636)
22. +-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo Antimicrob. Agents Chemother. 2011, 55, 1088-1096
23. Teulon, J. M. EP162776, 1985.
24. Sidhu, G. S.; Thyagarajan, G.; Ansari, S. Syntheses of carbostyrils and dihydrocarbostyrils Liebigs Ann. Chem. 1959, 627, 218-224
25. Clark, J. D.; Davis, J. M.; Favor, D.; Fay, L. K.; Franklin, L.; Henegar, K. E.; Johnson, D. S.; Nichelson, B. J.; Ou, L.; Repine, J. T.; Walters, M. A.; White, A. D.; Zhu, Z. Unpublished results, 2005.
26. Chen, P.; Barrish, J. C.; Iwanowicz, E.; Lin, J.; Bednarz, M. S.; Chen, B.-C. Reaction of quinoxalin-2-ones with TosMIC reagent: synthesis of imidazo[1,5- a ]quinoxalin-4-ones Tetrahedron Lett. 2001, 42, 4293-4295 (Pubitemid 32524125)
27. Curd, F. H. S.; Davey, D. G.; Stacey, G. J. Synthetic antimalarials. XL. The effect of variation of substituents in 2-chloro-3-(2-diethylaminoethylamino) quinoxaline J. Chem. Soc. 1949, 1271-1277
28. Kiyoto, T.; Ando, J.; Tanaka, T.; Tsutsui, Y.; Yokotani, M.; Noguchi, T.; Ushiyama, F.; Urabe, H.; Horikiri, H. WO2007138974, 2007.
29. Barvian, M.; Boschelli, D.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido[2,3- d ]pyrimidin-7-one inhibitors of cyclin-dependent kinases J. Med. Chem. 2000, 43, 4606-4616
30. Schmidt, K. J.; Hammann, I. DE1809390, 1970.
31. Hay, M. P.; Gamage, S. A.; Kovacs, M. S.; Pruijn, F. B.; Anderson, R. F.; Patterson, A. V.; Wilson, W. R.; Brown, J. M.; Denny, W. A. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine J. Med. Chem. 2003, 46, 169-182 (Pubitemid 36043797)
32. Joyeau, R.; Felk, A.; Guilaume, S.; Wakselman, M.; Vergely, I.; Doucet, C.; Boggetto, N.; Reboud-Ravaux, M. Synthesis and inhibition of human leukocyte elastase by functionalized N -aryl 2-azetidinones: effect of different substituents on the aromatic ring J. Pharm. Pharmacol. 1996, 48, 1218-1230 (Pubitemid 27035909)
33. Vermeulen, E. S.; Van Smeden, M.; Schmidt, A. W.; Sprouse, J. S.; Wikstroem, H. V.; Grol, C. J. Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline- based arylsulfonamides J. Med. Chem. 2004, 47, 5451-5466 (Pubitemid 39382794)
34. Caliendo, G.; Perissutti, E.; Santagada, V.; Fiorino, F.; Severino, B.; d'Emmanuele di Villa Bianca, R.; Lippolis, L.; Pinto, A.; Sorrentino, R. Synthesis and vasorelaxant activity of new 1,4-benzoxazine derivatives potassium channel openers Bioorg. Med. Chem. 2002, 10, 2663-2669 (Pubitemid 34626229)
35. Reddy, P. S. N.; Reddy, P.; Reddy, G. J.; Rao, K. S. Synthesis of pyrazolo[3,4:4,5]pyrimido[2,3- c ][1,4]benzoxazines. A new heterocyclic ring system Heterocycl. Commun. 2003, 9, 503-506 (Pubitemid 38223045)
36. Gogte, V. N.; Kulkarni, S. B.; Tilak, B. D. Synthesis of heterocyclic compounds: part XX. 2,4-Disubstituted 1,2,3,4-tetrahydroquinolines Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1977, 15B, 769-773
37. Turner, J. A. A general approach to the synthesis of 1,6-, 1,7-, and 1,8-naphthyridines J. Org. Chem. 1990, 55, 4744-4750
38. Davies, D. T.; Elder, J. S.; Forrest, A. K.; Jarvest, R. L.; Pearson, N. D.; Sheppard, R. J. WO2004014361, 2004.
39. Axten, J. M.; Daines, R. A.; Davies, D. T.; Gallagher, T. F.; Jones, G. E.; Miller, W. H.; Pearson, N. D.; Pendrak, I. WO2004002992, 2004.